Intranasal H102 Peptide-Loaded Liposomes for Brain Delivery to Treat Alzheimer’s Disease
Authors:
- 26 June 2015
- journal article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 32 (12) , 3837-3849
Abstract
H102, a novel β-sheet breaker peptide, was encapsulated into liposomes to reduce its degradation and increase its brain penetration through intranasal administration for the treatment of Alzheimer’s disease (AD). The H102 liposomes were prepared using a modified thin film hydration method, and their transport characteristics were tested on Calu-3 cell monolayers. The pharmacokinetics in rats’ blood and brains were also investigated. Behavioral experiments were performed to evaluate the improvements on AD rats’ spatial memory impairment. The neuroprotective effects were tested by detecting acetylcholinesterase (AchE), choline acetyltransferase (ChAT) and insulin degrading enzyme (IDE) activity and conducting histological assays. The safety was evaluated on rats’ nasal mucosa and cilia. The liposomes prepared could penetrate Calu-3 cell monolayers consistently. After intranasal administration, H102 could be effectively delivered to the brain, and the AUC of H102 liposomes in the hippocampus was 2.92-fold larger than that of solution group. H102 liposomes could excellently ameliorate spatial memory impairment of AD model rats, increase the activities of ChAT and IDE and inhibit plaque deposition, even in a lower dosage compared with H102 intranasal solution. H102 nasal formulations showed no toxicity on nasal mucosa. The H102-loaded liposome prepared in this study for nasal administration is stable, effective and safe, which has great potential for AD treatment.Keywords
This publication has 41 references indexed in Scilit:
- Pharmacological Characterization of Memoquin, a Multi-Target Compound for the Treatment of Alzheimer's DiseasePLOS ONE, 2013
- Fast and robust extraction of hippocampus from MR images for diagnostics of Alzheimer's diseaseNeuroImage, 2011
- Interactions of AChE with A? Aggregates in Alzheimer?s Brain: Therapeutic Relevance of IDN 5706Frontiers in Molecular Neuroscience, 2011
- A rational design to create hybrid β-sheet breaker peptides to inhibit aggregation and toxicity of amyloid-βMedChemComm, 2010
- Intranasal delivery to the central nervous system: Mechanisms and experimental considerationsJournal of Pharmaceutical Sciences, 2010
- Delivery of Nerve Growth Factor to Brain Via Intranasal Administration and Enhancement of Brain UptakeJournal of Pharmaceutical Sciences, 2009
- In situ gel based on gellan gum as new carrier for nasal administration of mometasone furoateInternational Journal of Pharmaceutics, 2009
- Endothelin-converting enzyme-1 is expressed in human cerebral cortex and protects against Alzheimer's diseaseMolecular Psychiatry, 2004
- Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivoNature, 2002
- Estimation of Variance for AUC in Animal StudiesJournal of Pharmaceutical Sciences, 1993